Prostate cancer is among the most common male malignancies worldwide, with recent advances in molecular imaging and targeted radiopharmaceutical therapy revolutionizing its management. PSMA has become a key theranostic target, enabling highly sensitive disease detection via PSMA PET/computed tomography (CT) imaging and effective treatment with PSMA-directed radioligand therapy. While PSMA theranostics are now standard in advanced prostate cancer care, increasing adoption strains specialist capacity and introduces variability in interpretation. Artificial intelligence (AI) and machine learning are poised to enhance this field by improving imaging accuracy, patient selection, treatment planning, and response monitoring.